Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.

Nicola Alexander Hanania Scott CaveneyTedi SouleLee TombsSally Lettis Courtney Crim Byron M Thomashow Hitesh Patel Isabelle H Boucot

Published in: International journal of chronic obstructive pulmonary disease (2021)

These data provide evidence to support the use of FF/VI, UMEC, or UMEC + FF/VI, all delivered via the ELLIPTA DPI, to treat older (≥65 years) and younger (<65 years) patients with COPD.

Keyphrases

chronic obstructive pulmonary disease
physical activity
electronic health record
big data
lung function
machine learning
middle aged